NCL statement on FDA review of the oral toxicity of cannabidiol (CBD)

Researchers from the Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, Food and Drug Administration (FDA) recently published an analysis on the toxicity of cannabidiol (CBD).

NCL Chief Executive Officer, Sally Greenberg, said, "These findings unfortunately further validate our concerns around the risks, including negative drug-drug interactions, disruption of critical metabolic pathways, liver injury, reproductive toxicity, and more.”

Read the full statement here.